ABSTRACT
Introduction The introduction of the serum prostate-specific antigen (PSA) has changed the presentation of prostate cancer worldwide. Patients now present at a younger age, with lower grade disease, and are more likely to have organ-confined cancers found upon pathologic evaluation of the radical prostatectomy specimen.1 This migration toward smaller volume disease raises the possibility of more tailored therapy.
